
-
Brainstorm Cell Therapeutics NasdaqCM:BCLI Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Location: 1325 Avenue of Americas, New York, NY, 10019, United States | Website: https://www.brainstorm-cell.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
8.987M
Cash
1.644M
Avg Qtr Burn
N/A
Short % of Float
3.35%
Insider Ownership
15.98%
Institutional Own.
12.89%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NurOwn (autologous MSC-NTF) (Debamestrocel) Details Amyotrophic lateral sclerosis | Phase 3 Initiation | |
NurOwn (autologous MSC-NTF) (Debamestrocel) Details Multiple sclerosis | Failed Discontinued |